The TIOB - Collection of Patients' Biospecimens for Analysis of Immunological and Molecular Biomarkers.

Phase

N/A

Condition

Cancer

Treatment

N/A

Clinical Study ID

NCT05371756

019-350

All Genders
Accepts Healthy Volunteers

Study Summary

The purpose of the Texas Immuno-Oncology Biorepository (TIOB) is to collect and store well-defined and well-annotated serial biospecimens of tissue, blood, urine and stool in a longitudinal manner from cancer patients who are receiving either standard of care surgical interventions and or FDA approved immunotherapeutics across the largest not-for-profit health system in Texas. Comprehensive clinical and radiological data from a diverse population of patients with different racial, social and ethnic backgrounds matched with serial biospecimens over a patients journey with cancer marks the TIOB as a unique research facility.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Understand and willingness to sign written informed consent method.
Patients who are suspected by a physician of being at risk for developing cancer.
Patients with confirmed or clinically suspected malignancy by a physician. Thisincludes but is not limited to candidates for immunotherapy, surgical candidates,patients receiving Standard of Care drugs, immunotherapy drugs, participating on aclinical trial with immunotherapy drugs, patients who have received immunotherapydrugs in the past, patients with any other approved or investigational diseasemanagement.

Exclusion

Exclusion Criteria:

Patients unwilling to donate blood
Patients unwilling to provide informed consent for the collection of fresh orarchived tumor tissue.

Study Design

September 11, 2020

September 11, 2052

Study Description

The goal of establishing the Texas Immuno-Oncology Biorepository (TIOB) is to create a research facility that purposely consents patients to collect, catalog, process, store, and analyze biospecimens with well-annotated clinical/radiological data from patients receiving surgical interventions or immunotherapeutics in our combined clinics throughout Texas. Potential types of studies that will be enabled by this resource will include but are not limited to (a) morphological studies including immunohistochemistry, (b) genomic and molecular analysis, including circulating, cell-free DNA, RNA, as well as extracellular vesicles and their cargo, (c) proteomic analysis involving protein isolation, (d) interrogation of circulating immune cells as well as the underlying tumor immune microenvironment, and (e) single-cell and spatial transcriptomics. Correlation of these studies with clinical, treatment outcome, and demographic information will be possible. Translation of multi-omics technologies will be a key feature of the TIOB and data integration strategies including genomics, epigenomics, transcriptomics, proteomics, radiomics, metabolomics and microbiomics will be possible and offer opportunities to improve our understanding of the complex biological interactions that define cancer.

Connect with a study center

Baylor Scott & White Research Institute
Dallas, Texas 75246
United States
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.